David Bunton, CEO, REPROCELL Europe
Who we are
REPROCELL Europe is a leading life sciences company focussed on products and services to improve the drug discovery process. Biopta, now part of REPROCELL, started as a spin-out from Glasgow Caledonian University in 2002.
I was a lecturer at the university at the time and was interested in developing technologies to improve the drug discovery process. Together with my co-founder, we recognised a gap in the process that could be addressed by the use of human fresh tissues and saw that it had enormous commercial and scientific potential.
In 2015, Biopta was acquired by REPROCELL, a Japanese stem cell research company based in Yokohama. REPROCELL Europe, formed from the merger of Biopta and Reinnervate, a tissue bioengineering spin-out from Durham University, which had been acquired by REPROCELL in 2014, is now the centre of REPROCELL’s Predictive Drug Discovery Services, using human tissue and stem cell research to accelerate drug development.
What we do
At REPROCELL, we are passionate about human-centred research and making translational science available globally. Despite the broad range of products and services we offer, they all aim to better translate discoveries into therapies. As a team of innovators we are keen to contribute to novel therapeutics in precision medicine, regenerative medicine, and mRNA technologies.
What is it like to work for REPROCELL Europe?
As REPROCELL Europe continues to grow, we are always on the look-out for professional, talented, and ambitious individuals. We like to hire employees who value technological advancement, as we consider ourselves innovators in the drug development field. Specific areas of expertise we focused on include ex vivo research, stem cell technologies, and precision medicine.
As a young, dynamic company, there are significant opportunities for career progression at REPROCELL. Some staff members have stayed with us for over 10 years, progressing from entry-level positions to senior management during that time. We are lucky to employ so many talented individuals, something which can be attributed in part to Scotland’s extensive pool of life-science graduates.
One of the reasons REPROCELL was interested in buying Biopta is because the Scottish life science sector has so much potential. The industry has grown from strength to strength in recent years, giving companies access to the best talent and outsourcing. For maximum clinical relevance it is important to us that the tissues we use are of the highest quality provided with the informed consent of donors.
Our location in Scotland has allowed access to a network of NHS biorepositories and clinical sites that can provide human biospecimens with anonymised clinical data, an important factor in developing precision medicines.
REPROCELL’s most recent Precision Medicine publication demonstrated the power of combining forces across the Scottish precision medicine ecosystem. In addition to my role at REPROCELL, I am also Chairman of the Precision Medicine Scotland Innovation Centre, based at the Queen Elizabeth University Hospital, which is maximising the potential of “Triple Helix” of industry, academia, and the NHS towards patient benefit.
I believe that Scotland will be at the forefront of innovation in Precision Medicine in the next decade and REPROCELL aims to play its part in the success of the sector.
We always want to hear from talented individuals that are eager to join our team. Check out our vacancies.